He doesn't believe PRs make a difference in stock price and explicitly stated he isn't going to PR something to move the stock price in just this last CC. If he feels it a PR will negatively affect Elite's long-term financials (for instance by giving heads up to competitors on when to time their contract renewal to make it difficult for Elite to get contracts with a new product) he isn't going to do it like he didn't do it with the insufflation study. If a competitor has less than a year in a contract they have less opportunity to mess with Elite's access to new customers. Letting the cat out of the bag more than a year out can let competitors address the additional competition in the next renewal. He talked about this being a problem with the Adderall ER rollout.